$MYO

Mitchell Micah sold $78K of MYO

Mitchell Micah (Chief Commercial Officer) sold 90,231 shares of MYOMO, INC. (MYO) at $0.86 on 2026-05-14.

Original reporting
SEC EDGAR · Mitchell Micah
Published Jun 8, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MYO
Neutral
high confidence
Mentioned
$MYO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYONeutralLow
01

Why it matters

This adds a new, primary-source datapoint on insider ownership changes, but it does not disclose any new company operational or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The article provides only the sale details; it does not include context like option exercises, compensation timing, or whether other insiders are buying/selling around the same period.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-08 (covers sale dated 2026-05-14).

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for MYOMO, Inc. (MYO).

Company-level read

Ticker impact

$MYONeutralHigh confidence
Context

SEC Form 4 shows MYO chief commercial officer Mitchell Micah sold 90,231 shares in an open-market transaction on 2026-05-14.

Expected impact

Low near-term impact; any effect is likely sentiment-only unless follow-on filings show accelerated selling or other corporate developments.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, contracts, litigation, or regulatory action) in the article.

Market effects

No sector-level read-across; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan does not automatically imply negative fundamentals.

Key entities

  • MYOMO, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Mitchell Micah

    Chief Commercial Officer who sold shares via an open-market sale.

Related articles

$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 myo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guida

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.